Abstract
Background: Bioanalytical methods were required to study the novel anticancer drug, RRx-001 preclinically and for clinical pharmacokinetic analysis; however, RRx-001 quickly and completely disappeared on intravenous administration in preclinical species. Results: Quantification of RRx-001 directly or by derivatization was unsuccessful. On exposure to whole blood, RRx-001 formed the glutathione (GSH) adduct very rapidly, suggesting this metabolite as the bioanalyte. However, rapid enzymatic degradation in the blood matrix of RRx-001-GSH posed significant technical problems. Herein, we describe a novel and broadly applicable solution to stabilize GSH conjugates in blood samples by inhibiting the degrading enzyme. Liquid chromatography–tandem mass spectrometry methods for analysis of RRx-001-GSH in rat, dog and human plasma were developed and successfully validated to good laboratory practice standards. Conclusion: Extensive breakdown of RRx-001-GSH was effectively stopped by addition of the enzyme inhibitor, acivicin. The developed liquid chromatography–tandem mass spectrometry assay for RRx-001-GSH was validated for use in preclinical toxicology studies and the Phase I first-in-human clinical trial.
Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest
References
- 1 Radiorx, Inc., Alliant Techsystems Inc.: US7507842 (2009).
- 2 Oronsky B, Scicinski J, Reid T, Knox S. Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review. Transl. Oncol.5(3),133–140 (2012).
- 3 Straessler N, Lesley M, Cannizzo L. Development of a safe and efficient two-step synthesis for preparing 1-bromoacetyl-3, 3-dinitroazetidine, a novel clinical anticancer candidate. Org. Process Res. Dev.16(3),512–517 (2012).
- 4 Brennan P, Downie I, Langdon J, Zaki G. Emerging role of nitric oxide in cancer. Br. J. Oral Maxillofac. Surg.37(5),370–373 (1999).
- 5 Muntane J, La Mata M. Nitric oxide and cancer. World J. Hepatol.2(9),337–344 (2010).▪▪ Seminal paper describing the role of nitric oxide in cancer.
- 6 Yasuda H. Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric Oxide19(2),205–216 (2008).
- 7 Scatena R, Bottoni P, Pontoglio A, Giardina B. Pharmacological modulation of nitric oxide release: new pharmacological perspectives, potential benefits and risks. Curr. Med. Chem.17(1),61–73 (2009).
- 8 Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, Knox S. Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res.72(10),2600–2608 (2012).▪▪ Describes the preclinical research leading to the discovery of RRx-001.
- 9 Scicinski J, Oronsky B, Taylor M et al. Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent. Drug Metab. Dispos.40(9),1810–1816 (2012).
- 10 Oronsky B, Reid T, Knox S, Scicinski J. The scarlet letter of alkylation: a mini review of selective alkylating agents. Transl. Oncol.5(4),226–229 (2012).▪ Selectivity of covalently binding drugs is key to their success. This review describes three alkylating agents with different selectivity strategies.
- 11 Singh J, Petter R, Baillie T, Whitty A. The resurgence of covalent drugs. Nat. Rev. Drug Discov.10(4),307–317 (2011).▪ Charts the resurgence of covalently binding drugs.
- 12 Ortega A, Mena S, Estrela J. Glutathione in cancer cell death. Cancers (Basel)3(1),1285–1310 (2011).
- 13 Boyle R, Travers S. Hypoxia: targeting the tumour. Anticancer Agents Med. Chem.6(4),281–286 (2006).▪▪ Hypoxia is a key attribute of the tumor microenvironment. This article describes methods to exploit hypoxia for therapeutic targeting.
- 14 Mitrea N, Leblanc A, St-Onge M, Sleno L. Assessing covalent binding of reactive drug metabolites by complete protein digestion and LC–MS analysis. Bioanalysis2(7),1211–1221 (2010).
- 15 Orioli M, Aldini G, Beretta G, Facino R, Carini M. LC–ESI-MS/MS determination of 4-hydroxy-trans-2-nonenal Michael adducts with cysteine and histidine-containing peptides as early markers of oxidative stress in excitable tissues. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.827(1),109–118 (2005).
- 16 Rappaport S, Li H, Grigoryan H, Funk W, Williams E. Adductomics: characterizing exposures to reactive electrophiles. Toxicol. Lett.213(1),83–90 (2011).
- 17 Wen B, Fitch W. Analytical strategies for the screening and evaluation of chemically reactive drug metabolites. Expert Opin. Drug Metab. Toxicol.5(1),39–55 (2009).
- 18 Blair I. Analysis of endogenous glutathione-adducts and their metabolites. Biomed. Chromatogr.24(1),29–38 (2009).
- 19 Fitch W, Berry P, Tu Y et al. Identification of glutathione-derived metabolites from an IP receptor antagonist. Drug Metab. Dispos.32(12),1482–1490 (2004).
- 20 Silva R, Boldt S, Costa V et al. Evaluation of GSH adducts of adrenaline in biological samples. Biomed. Chromatogr.21(7),670–679 (2007).
- 21 Whitfield J. Gamma glutamyl transferase. Crit. Rev. Clin. Lab. Sci.38(4),263–355 (2001).▪▪ This is a general review on the role of γ-glutamyl transferases.
- 22 Tso J, Bower S, Zalkin H. Mechanism of inactivation of glutamine amidotransferases by the antitumor drug L-(alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125). J. Biol. Chem.255(14),6734–6738 (1980).▪ Describes the mechanism of action of acivicin against γ-glutamyl transpeptidase.
- 23 Smith T, Ikeda Y, Fujii J, Taniguchi N, Meister A: Different sites of acivicin binding and inactivation of gamma-glutamyl transpeptidases. Proc. Natl Acad. Sci. USA92(6),2360–2364 (1995).
- 24 Wickham S, Regan N, West M et al. Inhibition of human gamma-glutamyl transpeptidase: development of more potent, physiologically relevant, uncompetitive inhibitors. Biochem. J.450(3),547–557 (2013).
- 25 Kannan R, Yi JR, Zlokovic BV, Kaplowitz N. Molecular characterization of a reduced glutathione transporter in the lens. Invest. Ophthalmol. Vis. Sci.36,1785–1792 (1995).
